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Artificial urinary sphincter implantation: what do patients and
urologists face?
Adnan ŞİMŞİR, Raşit ALTINTAŞ, Mehmet Ceyhun ÖZYURT

Aim: To investigate the main problems faced by patients undergoing artificial urinary sphincter (AUS) implantation and
the important factors that the surgeon should take into consideration in predicting these problems. Postprostatectomy
incontinence continues to be a complication that most severely impairs the quality of life.
Materials and methods: Of 82 initial patients, 64 patients with complete data who responded positively to the invitation
for examination were divided into 3 groups: patients with implant-tissue interaction, patients with no problems, and
those with mechanical failure. Univariate analysis, Student’s t-test, Pearson’s chi-square test, logistic regression, and
Kaplan-Meier analysis were used in this study.
Results: Of the 64 patients, 20 (31.2%) were reoperated on with a mean follow-up of 62 (range: 1-120) months. It was
found that the risk of urethral erosion was higher in patients with obesity (P = 0.04), diabetes (P < 0.0001), radical
prostatectomy (P < 0.0001), and adjuvant radiotherapy (P < 0.0001), and in those with the suspicion of urethral stricture
who would undergo sphincter implantation within at least 3 months after the latest surgical treatment of urethral
stricture, compared to other patients (P < 0.0001). Additionally, we found that surgical experience also had a strong
effect on the risk of urethral erosion.
Conclusion: Given increasing medicolegal awareness, patients should be informed of the possible need for reoperation,
and those in the specific patient groups mentioned above should particularly be notified of a higher risk before
implantation of an AUS.
Key words: Urinary sphincter, artificial, erosion, incontinence, prostatectomy

Yapay üriner sfinkter uygulaması: Hastayı ve üroloğu neler bekliyor?
Amaç: Post-prostatektomik inkontinans yaşam kalitesini en ağır derecede bozan komplikasyon olmaya devam ederken,
şiddetli inkontinansı olan olgularda artifisial üriner sfinkter implantasyonu halen altın standart tedavi yöntemidir.
Bu çalışmada AUS implantasyonu uygulanan hastaları bekleyen belli başlı sorunlar ve cerrahın bu sorunları predikte
edebilmesi için dikkat etmesi gerekenler araştırılmıştır.
Yöntem ve gereç: Verilerine tam olarak ulaşılabilen ve kontrol davetine olumlu yanıt veren 64 hasta; doku-cihaz
etkileşimi gelişenler, sorun yaşamayanlar ve mekanik problem yaşayan hastalar olarak 3 gruba ayrılıp incelendiler.
Univariete analiz, Student’s t-test ve chi-square, logistic regresyon analizi ve Kaplan-Meier analizleri araştırmada
kullanıldı.
Bulgular: 64 hastanın 20’si (% 31,2) reopere edildi ve ortalama takip süreleri 62 (1-120) ay idi. Obez (P = 0,04), diabetik
(P < 0,0001), radikal prostatektomili (P < 0,0001), adjuvan radyoterapi almış (P < 0,0001), üretral striktür kuşkusu olan
ve striktürün son cerrahi tedavisinden bu yana en az 3 ay geçmeden sfinkter implantasyonu uygulanacak (P < 0,0001)
hastalarda üretral erozyon gelişme riskinin diğer hastalara kıyasla daha yüksek olduğu izlendi. Ayrıca cerrahi deneyimin
de birebir üretral erozyon riskini etkilediği saptandı.
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Sonuç: Artan medikolegal uygulamalar nedeniyle artifisyal uriner sfinkter implantasyonu öncesinde hastalara
reoperasyon gerekebileceğinden, şayet hasta yazıda bahsi geçen özellikli hasta gruplarından ise bu riskin daha da yüksek
olabileceğinden bahsedilmelidir.
Anahtar sözcükler: Üriner sfinkter, yapay, erozyon, inkontinans, prostatektomi

Introduction
Urinary incontinence (UI) after prostatectomy
is a complication that most severely impairs the
quality of life and interferes with social life (1,2).
The incidence of UI following surgery for benign
prostatic hyperplasia (BPH) has been reported as
1%-5%, whereas the incidence of UI after radical
prostatectomy (RP) has been reported to range
between 8% and 77% (3). It is also known that 6%7% of the patients undergoing RP need further
surgical treatment for UI (4,5). Today, artificial
urinary sphincter (AUS) implantation remains the
gold standard surgical technique for the treatment of
postprostatectomy incontinence (PPI) (6).
Even though AUS implantation is a successful
and reliable procedure, approximately 25%-28%
of the patients require reoperation (4-6). The most
serious complication leading to the requirement for
reoperation is urethral cuff erosion, which occurs in
approximately 5% of cases.
In this study, the main problems faced by
patients undergoing AUS implantation for PPI by 2
different surgeons at a single institution since 2001
were investigated. We also attempted to identify the
important factors that the surgeon should take into
consideration in predicting these problems and ways
of dealing with them.
Materials and methods
Initially, 82 patients who underwent AUS (AMS
800R, American Medical Systems, Minnetonka, MN,
USA) implantation with 2 different surgeons at a
single institution between January 2001 and January
2011 were enrolled in this study. Of these patients,
7 whose indications were not PPI were excluded
from the study. First, we retrospectively reviewed the
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medical records of the patients. The data recorded
included the patient’s general characteristics at the
time of AUS implantation, the type of prostatectomy
procedure
(transurethral
resection
(TUR),
suprapubic transvesical prostatectomy (SPTVP), and
RP), previously received adjuvant or neoadjuvant
therapy for cancer treatment, urodynamic data,
pad test results, history of urethral or bladder neck
stricture and the number and type of operations
undergone by patients thereof (endoscopic incision
or resection), the time from the last operation to the
implantation (stricture-free time), and postoperative
early and late complications and the procedures
performed for these complications. Subsequently,
all of the patients reached by telephone were invited
for an examination. Of those patients, 64 responded
positively to the invitation and were enrolled in
the study. Thereafter, problems experienced by the
patients during the period from implantation to the
day of the study and rates of dryness were determined
by medical history, and the patients underwent a
urogenital examination and uroflowmetry.
Operative technique: During preoperative
preparation, all of the patients received 1 g of a
first-generation cephalosporin intravenously 30
min before the procedure. With the patients in the
lithotomy position, the surgical site was cleaned with
povidone-iodine solution, and then the operation
began. After 12 h, parenteral administration of
antibiotics was repeated and a first-generation oral
cephalosporin was administered to the patients
with instructions to receive it for 7 days, beginning
from the first postoperative day. The review of the
medical records revealed that the procedure was
performed through a perineal approach using the
2-incision technique in 24 of the 64 patients, whereas
the procedure was performed through a single
transverse penoscrotal incision in the remaining

A. ŞİMŞİR, R. ALTINTAŞ, M. C. ÖZYURT

patients, with the cuff placed around the bulbar
urethra in each patient. All of the patients underwent
a cystoscopy immediately before the procedure, and
the implantation was performed at least 1 month
after treatment in patients with urethral or bladder
neck stricture. All of the patients had the urethral
catheters removed at 24 h after the operation, and
they were discharged after being instructed to begin
operating the device 6 weeks later.
Statistical analysis: The data obtained were
analyzed with the patients divided into 3 groups:
Group 1, patients reoperated on for implant-tissue
interaction (such as fistula or erosion); Group
2, patients who had no complaints and were not
reoperated on; and Group 3, patients reoperated on
for mechanical failure (Table 1). Statistical analyses
were performed using univariate analysis, Student’s
t-test, Pearson’s chi-square test, logistic regression,
Kaplan-Meier analysis, and SPSS 15. P < 0.05 was
considered statistically significant.

Table 2. The characteristics of the patients.
Characteristics

No.

Number of patients
64
Mean age (years)
62 (53-74)
BMI 24.5 (21-30)
Comorbid diseases
DM
13
COLD*
10
Hypertension
13
Neurologic diseases
3
Types of prostate surgery
TUR
3
SPTVP
5
RP
56
Number of patients receiving adjuvant therapy
Radiotherapy
13
Hormonotherapy
2
Urodynamic findings before AUS implantation (mean)
Q max (mL/m)
11 (5-19)
Max. capacity (cc)
274 (185-326)
23 (11-42)
Max. DP** (cmH2O)
9.2 (3-17)
Compliance (mL/cmH2O)
Pad test (g/24 h)
686 (420-1280)
Number of patients reoperated on
20 (31.2%)

Results
We found that 20 (31.2 %) of the 64 patients
undergoing AUS implantation for PPI, whose data
were available and who responded positively to
the examination invitation, were reoperated on.
The mean follow-up period was 62 (range: 1-120)
months, whereas the interval between implantation
and reoperation was 10 (range: 0-25) months.
The mean complication-free time was found to be
approximately 62 months. Table 2 summarizes the
characteristics of the patients.

*Chronic obstructive lung disease
**Detrusor pressure

Group 1: 11 patients reoperated on for implanttissue interaction
All of the 11 patients in this group had urethral
erosion, whereas 1 patient also had accompanying
pump erosion through the skin. All of these
patients had been admitted with complaints of
scrotal swelling and inability to void. Erosion after
implantation was found to occur frequently in

Table 1. Patient groups and study design.
Group 1:
Patients reoperated on for implant-tissue interaction (urethral erosion, skin erosion, etc.) after AUS implantation.
Group 2:
Patients who had no complaints or mechanical failures of the device and who were not reoperated on after AUS implantation.
Group 3:
Patients reoperated on for mechanical failure of the device or a decrease in cuff pressure due to urethral atrophy after AUS implantation.
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The comparison of patients with and without
erosion revealed that RP (P = 0.05), a decrease in
pad weight (P = 0.04), increased body mass index
(BMI) (P = 0.04), DM, preoperative low urinary flow
rates (P = 0.03), history of stricture (P = 0.04), and
stricture-free time (P < 0.0001) also affected the risk
of erosion (Table 4).

the early postoperative period, at an average of 2
months (range: 0-24). A univariate analysis revealed
that, among the parameters that are likely to cause
urethral cuff erosion, undergoing RP (P < 0.0001),
a history of adjuvant radiotherapy (P < 0.0001), and
accompanying diabetes mellitus (DM) (P = 0.02)
caused erosion. The comparative analyses showed an
inverse correlation between the increased number
of patients and rates of erosion for the surgeon who
performed 47 implantations and the surgeon who
performed 17 implantations (P < 0.0001) (Table 3).

Similarly, for multivariate analysis, DM (P <
0.001), urethral stricture (P < 0.001), and a history of
radiotherapy predicted urethral erosion. With KaplanMeier analysis, it was interesting to see that patients

Table 3. Comparison of the results of 2 different surgeons.

Number of patients
Age (mean)
DM (%)
Pad test (g)*
History of urethral stricture (%)
Number of patients reoperated on* (%)
Urethral erosion* (%)
Urethral atrophy* (%)
Cuff replacement (%)

Surgeon 1

P

Surgeon 2

47
61.7
9 (19.2)
827
27 (57.4)
13 (27.7)
6 (12.8)
5 (10.6)
2 (4.25)

0.62
0.17
0.04
0.91
<0.0001
<0.0001
<0.0001
0.42

17
64.6
4 (23.5)
580
10 (58.8)
7 (41.1)
5 (29.4)
1 (5.9)
1 (5.88)

*Parameters showing statistical significance
Table 4. The association of study groups with the parameters investigated*.

Number (%)
Age (mean)
BMI
DM (%)
Prostatectomy indication
BPH (%)
Carcinoma (%)
Adjuvant radiotherapy (%)
Pad test (g/24 h)
Urodynamic data (mean)
Q max (mL/m)
Max. capacity (cc)
Max. DP*** (cmH2O)
Compliance (mL/cmH2O)
History of stricture
Stricture-free time (weeks)

Group 1

P

Group 2

P

Group 3

11 (17.2)
59.8
28.2
8 (72.7)

0.82
0.04**
<0.0001**

44 (68.7)
63.2
23.7
4 (9.1)

0.75
0.45
0.27

9 (14.1)
63.4
24.3
1 (11.1)

1 (9.1)
10 (90.9)
10 (90.9)
650

0.06
0.05**
<0.0001**
0.04**

6 (13.6)
38 (86.4)
2 (4.54)
980

0.91
0.07
0.09
0.56

1 (11.1)
8(88.9)
1 (11.1)
820

6.8
284.6
18.3
6.4
6 (54.6)
6.3

0.03**
0.68
0.19
0.07
0.04**
<0.0001**

13.2
270.5
17.2
10.5
26 (59.1)
27.4

0.34
0.74
0.38
0.85
0.06
0.07

11.4
292
17.9
19.2
5 (55.7)
13.1

*Pearson’s chi-square test and Student’s t-test were used.
**Parameters showing statistical significance.
***Detrusor pressure
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with a history of urethral stricture who underwent
implantation, had the highest rate of erosion in the
postoperative early period on approximately day 15,
which decreased rapidly after 5 months. The risk of
urethral erosion continued at a decreasing rate until
25 months in patients with a history of diabetes and
radiotherapy (Figure). All of the implants of the 11
patients who had urethral erosion were removed.
The patients with urethral catheters were followed
up for 20 days and, subsequently, their catheters
were removed after the absence of extravasation
was confirmed by urethrography. Implantation was
performed through a perineal approach using the
2-incision technique, enabling the surgeon to reach
more posterior regions, in 3 patients (both had been
operated on using a single penoscrotal incision)
who accepted to undergo reoperation at least 1 year
later; no complications were noted. The remaining 8
patients refused a reoperation. No significant results
were found between the type of incision and urethral
erosion.
Group 2: 44 patients who required no reoperation
after implantation
Analysis of the 44 patients in this group revealed that
38 (86.4%) patients were completely dry, whereas 6
patients (13.6%) presented minimal stress urinary
incontinence using 1 pad daily at most. We learned
that 1 patient was unable to use his hand due to

1.0

0.8
Radiotherapy (P < 0.001)
0.6
Diabetes mellitus (P < 0.001)
0.4

0.2
Urethral stricture (P < 0.001)

0.0
0

5

10
15
20
Urethral erosion time(month)

25

Figure. The relationship between predictive values and urethral
erosion time by Kaplan-Meier analysis.

cerebrovascular problems after implantation and the
pump was activated by his relative, whereas no other
problems were noted or reported.
Group 3: 9 patients reoperated on for mechanical
failure of the implant or decrease in cuff pressure
after implantation
Of the 9 patients in this group, 3 had the cuff
replaced due to mechanical problems. In 1 patient,
a suprapubic catheter was placed because of the
failure of the cuff to inflate 6 months after the
procedure and, subsequently, the cuff was examined
and replaced. The implant could not be activated
after the procedure in the other 2 patients, and the 2
cuffs that failed to inflate were replaced. No further
complications were noted in these 3 patients. At an
average of 9 (range: 4-26) months after the operation,
6 patients had severe incontinence due to a pressure
decrease in the cuff. Urethroscopy revealed that the
cuff, though inflated, failed to obstruct the urethra
completely, which was considered to be secondary
to urethral atrophy, and saline was added to the
reservoir, thus solving the problem. In the analyses
performed, no findings predisposing to urethral
atrophy were found (Table 4).
Discussion
AUS implantation remains the gold standard for
the treatment of severe urinary incontinence after
prostatectomy (6). This study has demonstrated that
approximately one-third of the patients undergoing
AUS implantation will require reoperation within
5 years. The most difficult complication to treat
after implantation is undoubtedly urethral erosion
(7). Patients in this study with increased BMI
had significantly higher rates of urethral erosion.
Given that obesity and microangiopathy are closely
related, impaired urethral support is highly likely
to cause a severe problem, such as erosion, in the
postoperative period. Similarly, Raj et al. reported a
significantly increased risk for urethral erosion due
to microangiopathy in the whole body in patients
with coronary artery disease (7). Additionally,
given that wound healing is poor and the procedure
is technically more difficult to perform in obese
patients, higher rates of urethral erosion in patients
with an increased BMI is not a coincidence. A similar
233
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situation was found for DM. It is well known that
DM is particularly associated with occlusion of small
vessels and predisposes to infection due to neutrophil
dysfunction (8,9). In this study, 73% of the patients
with urethral erosion had DM, which is consistent
with this finding.
Studies have reported a higher risk for incontinence
after RP compared to surgeries performed for BPH,
the cause of which is thought to be direct sphincter
damage or parasympathetic or somatic nerve damage
during RP (7,10). A higher rate of urethral erosion
in these patients was considered to be caused by a
problem in urethral support due to neurovascular
bundle damage and dissection during RP.
The relationship between adjuvant radiotherapy
and urethral cuff erosion has been addressed in
different ways in the literature. Radiotherapy is
known to induce small vessel occlusion, local tissue
hypovascularity and fibrosis, poor wound healing,
and impaired immunity against infection (11). A
study by Walsh et al. reported that patients receiving
adjuvant radiotherapy had a significantly higher risk
of urethral erosion compared to other patients, which
is consistent with our results (12). The studies by Lai et
al., Elliot and Barrett, and Manunta et al. also yielded
similar results (13-15). However, some authors, such
as Martins and Boyd and Perez and Webster, advocate
that implantation of an AUS should be attempted in
patients with postprostatectomy incontinence who
received adjuvant radiotherapy (16,17).
The other 3 parameters that were found to be
significantly associated with the risk of urethral
erosion were evaluated together since they were
considered to be correlated with each other. These
parameters were the pad test (P = 0.04), maximum
flow rate (P = 0.03), and history of stricture (P =
0.02). Severe incontinence is defined as urinary
leakage of greater than 400 g in the 24-h pad test. A
significantly lower rate of urinary leakage (650 g vs.
980 g) per day and urinary flow rates (6.8 vs. 13.2)
in the group with urethral erosion were considered
to be caused by intravesical obstruction. Thus, the
group with a history of stricture had a significantly
higher rate of erosion. Based on the literature data,
the AUS should be implanted after ensuring the
absence of recurrence for at least 3 months after the
latest surgical treatment of strictures of the urethra
234

or bladder neck (endoscopic incision or resection)
(7,12,18). It was also found that the stricture-free
time was significantly shorter (an average of 6 weeks
after the final treatment) in patients with urethral
erosion.
Another issue that was investigated here but
not found in the literature was the effect of surgical
experience on the outcome of patients with AUS
implantation. It is beyond doubt that surgical
experience increases in parallel with the increasing
number of patients operated on (19). There were no
significant differences in patient profiles between
the 2 surgeons, whereas the results obtained by the
second surgeon, who operated on 3 times fewer
patients than the other surgeon, were found to be
significantly complicated, which suggests that AUS
implantation is not as easy of an operation as it may
appear and surgical experience is of great importance
in performing this procedure, as in other surgeries.
In comparison with the current literature, the
limitations of this study were: 1) the number of the
patients was small, 2) the study was of a retrospective
design, and 3) the number of patients operated on by
one of the surgeons was much smaller than that by
the other surgeon. It is believed, however, that this
study will contribute to the literature by investigating
patients from a different geographic location
(different patient awareness and perceptions) and
by encouraging urologists who consider performing
this surgery.
Given increasing patient awareness and
medicolegal claims around the world today,
patients should be informed preoperatively about
the possible outcomes of an operation. Of patients
who will undergo AUS implantation, those with RP,
obesity, diabetes, a history of adjuvant radiotherapy,
and a history of recurrent strictures of the bladder
neck and urethra should particularly be informed
preoperatively and be reminded that, even in the
absence of problems, mechanical failure of the device
can occur, resulting in a need for further operation.
In addition, the urologist should perform the
procedure with the assistance of a surgical team until
he gains enough experience and should determine
the timing of implantation, taking into consideration
the stricture-free time.
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